Form 8-K - Current report:
SEC Accession No. 0001193805-21-001429
Filing Date
2021-10-08
Accepted
2021-10-08 08:40:44
Documents
14
Period of Report
2021-10-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e620998_8k-summit.htm   iXBRL 8-K 25752
2 e620998_ex99-1.htm EX-99.1 14002
6 GRAPHIC image_001.jpg GRAPHIC 7646
  Complete submission text file 0001193805-21-001429.txt   231459

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA smmt-20211007.xsd EX-101.SCH 3034
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE smmt-20211007_lab.xml EX-101.LAB 34916
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE smmt-20211007_pre.xml EX-101.PRE 22795
7 EXTRACTED XBRL INSTANCE DOCUMENT e620998_8k-summit_htm.xml XML 3663
Mailing Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 211313953
SIC: 2834 Pharmaceutical Preparations